Hyperhomocysteinaemia as a Risk Factor for Venous Thrombosis: An Update of the Current Evidence
Gespeichert in:
Verfasser / Beitragende:
[Martin den Heijer]
Ort, Verlag, Jahr:
2003
Enthalten in:
Clinical Chemistry and Laboratory Medicine, 41/11(2003-11-17), 1404-1407
Format:
Artikel (online)
Online Zugang:
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 378852272 | ||
| 003 | CHVBK | ||
| 005 | 20180305123326.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20031117xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/CCLM.2003.215 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/CCLM.2003.215 | ||
| 100 | 1 | |a Heijer |D Martin den | |
| 245 | 1 | 0 | |a Hyperhomocysteinaemia as a Risk Factor for Venous Thrombosis: An Update of the Current Evidence |h [Elektronische Daten] |c [Martin den Heijer] |
| 520 | 3 | |a Classical homocystinuria is associated with arterial vascular diseases and venous thrombosis. In the last decade, many studies, including some prospective studies, have been published indicating that moderate hyperhomocysteinaemia is also a risk factor for venous thrombosis. The 677C>T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinaemia. Recent meta-analyses show an elevated risk of venous thrombosis for subjects with the TT-genotype. Based on the concept of ‘Mendelian randomisation', this observation supports the hypothesis that hyperhomocysteinaemia is a causal risk factor for venous thrombosis. The results of one homocysteine-lowering trial regarding venous thrombosis are awaited at the end of 2003. In this paper the current evidence for hyperhomocysteinaemia as a risk factor for venous thrombosis is being discussed. | |
| 540 | |a Copyright (c) 2003 by Walter de Gruyter GmbH & Co. KG | ||
| 690 | 7 | |a Medical equipment & techniques |2 nationallicence | |
| 690 | 7 | |a Medical diagnosis |2 nationallicence | |
| 690 | 7 | |a Diseases & disorders |2 nationallicence | |
| 773 | 0 | |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/11(2003-11-17), 1404-1407 |x 1434-6621 |q 41:11<1404 |1 2003 |2 41 |o cclm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2003.215 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/CCLM.2003.215 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 100 |E 1- |a Heijer |D Martin den | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/11(2003-11-17), 1404-1407 |x 1434-6621 |q 41:11<1404 |1 2003 |2 41 |o cclm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||